• AG1’s diverse team of clinicians, researchers, and PhDs work together to build initial studies.
• The team conducted pre-clinical trials to inform the clinical trials. Pre-clinical studies were intentionally conducted to better understand the biological activity and mechanisms of AG1 – an approach that’s both common and foundational in the development of nutrition research. These early insights help inform the design of human clinical trials, enhancing scientific rigour and ensuring that future studies are strategically and effectively guided. Pre-clinical trials can take upwards of 8–10 months to design, implement and analyse the results.
• We then partnered with independent contract research organisations (CROs) – the same groups trusted by other companies and academic institutions – to ensure data collection and analysis were objective and professionally managed.
• To ensure scientific integrity and ethical compliance, each human study protocol was submitted for review and approval by an independent Institutional Review Board (IRB) prior to participant recruitment. IRB approval is a critical regulatory step that ensures the rights, safety, and well-being of study participants are protected, and that the research is conducted according to Good Clinical Practice (GCP) and applicable regulations. No human study began without formal IRB approval.
• We then created detailed protocols with third-party scientists (also known as principal scientists) outlining specific criteria including the study population, endpoints, duration, measurements, and statistical plan. The research partners then recruited participants to ensure the most objective outcome for each study design. Participants and the third-party researchers in the trials were “blinded,” meaning they did not know they were taking AG1 or a placebo. As part of the design, our scientists and statisticians helped determine the power of the study – which refers to the likelihood that the study would detect a true effect if one existed, ensuring the results would be scientifically meaningful and not due to chance.
• Each study was conducted over varying lengths of time, designed specifically to help answer the research questions – whether AG1 could measurably impact specific markers such as nutrient status, or microbiome composition in various populations from healthy individuals, active people to those with occasional gut issues.

• The institution that conducted the study analysed and interpreted the results, and presented the findings to us. Given the volume and complexity of biomarker and microbiome data, we also partnered with advanced data science teams to ensure robust and accurate interpretation.
• The data and research underwent strict scrutiny, not only from third-party scientists and statisticians, but also from our internal AG1 team including regulatory, research and legal teams.
• Together, we identified the most meaningful and measurable insights – both about individual ingredients and the formula as a whole – that shaped the development and launch of AG1, and that continue to inform how we communicate the science behind our products.

• We are committed to advancing scientific research through a level of integrity that goes well beyond the basic requirements for publication. The next phase of the publishing process starts with submitting abstracts – another word for summaries – to annual conferences.
• Once accepted, these submissions may be chosen for poster (a visual summary of research findings) or an oral presentation. Abstracts are typically published post-symposium, and the timing can vary depending on the scientific meeting.
• We’ve recently had abstracts accepted at several national scientific conferences, including:
  • 2025 American Physiology Summit (April 24–27), published here.
  • 2025 American Society of Nutrition (May 31–June 3)
  • 2025 American Society of Microbiology Annual Conference (June 19–23)
  • 2025 The International Society of Sports Nutrition Annual International Conference (June 23-25)
  • And more.
• These abstracts are under embargo, meaning we can’t share them until they are presented at the conferences listed above. As they are published, we will update this page.
• In parallel, AG1 is preparing full manuscripts containing more data from all four trials, which will be submitted to peer-reviewed journals over the coming months for publication.

AG1 has been studied across multiple clinical trials, consistently demonstrating its effectiveness in increasing nutrient levels and enriching the microbiome.

• Triple-blind, randomised, placebo-controlled trial (105 healthy adults who consumed a Standard American Diet) measuring nutrient biomarkers and microbiome changes.
• Double-blind, placebo-controlled crossover trial (20 highly active healthy adults) assessing microbiome changes.
• Double-blind, placebo-controlled crossover trial (24 healthy adults with occasional digestive discomfort) assessing microbiome changes.
• Double-blind, placebo-controlled crossover trial (16 healthy adults) measuring nutrient absorption and bioavailability.

At a high level, AG1 was shown to increase nutrient levels and enrich the microbiome. These results were consistent across multiple gold-standard clinical trials studying a range of lifestyles, including healthy adults who ate a Standard American Diet, highly active adults, and healthy adults experiencing occasional digestive discomfort. You can learn more on our site.

A gold standard clinical trial refers to a randomised, double-blind, placebo-controlled study. These types of trials are considered the highest-quality study design in scientific research because they minimise bias and ensure reliable, scientifically valid results.

Several AG1 reviews and studies have already been published in leading peer-reviewed journals, including Nutrients, Frontiers, Nutraceuticals, and the Journal of Functional Foods. In addition to publishing the methodology and results on our site, the latest research on AG1 has been submitted and is currently in the review process. The process is rigorous, and means the studies have been accepted after an in-depth evaluation by a panel of independent experts who ensure the data is accurate and unbiased.

We’re proud to hold some of the highest standards in the supplement category. Since 2010, we have earned the trust of millions of people around the world through our relentless approach to quality, efficacy, and safety.

This includes rigorously testing AG1 for hundreds of contaminants, including heavy metals, allergens, and over 500 herbicides and pesticides. Through Cologne List® and Informed Spot, two independent third-party programmes that certify dietary supplements are free from substances banned by major sporting organisations, we also test for over 250 banned substances, including stimulants, narcotics, diuretics, and masking agents.

You can read more about our standards and processes here.